Olaparib shows significant progression-free survival benefit in phase III SOLO2 trial Authors Christian Marth AGO-Austria and Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria DOI: https://doi.org/10.19156/cbn.2017.0041 Abstract No abstract available